Clinic to Commercial Manufacturing: Higher Titers and Product Quality with TransIT® AAViator GMP

TransIT®-Lenti Transfection Reagent – 5 x 1.5 mL

Ideal transfection reagent for recombinant lentivirus production

$2,754.00

Unsure of what transfection reagent you need? Consult Reagent AgentTM.

Description

TransIT®-Lenti Transfection Reagent is designed to enhance delivery of packaging and transfer vectors to adherent HEK 293T and suspension 293-F cell types to increase recombinant lentivirus production.

The TransIT® Lentivirus System combines the benefits of TransIT®-Lenti with the Lentivirus Packaging Mix Powered by MISSION® Genomics to produce even higher functional titers.

  • High Performance – Provide higher functional titers
  • Simple Protocol – No media change required, single harvest
  • Animal Origin Free  Regulatory friendly

 

SKU: MIR 6605

Supporting Data

High Functional Titers with TransIT®-Lenti Transfection Reagent. Adherent 293T/17 cells were transfected in a 6-well plate with pLKO.1-puro-CMV-TurboGFP™ transfer vector and the Lentivirus Packaging Mix Powered by MISSION® Genomics (1:1 ratio, 2 µg/well) with the following reagents: TransIT®-Lenti (3:1, vol:wt), Lipofectamine® 2000 (3:1), Lipofectamine® 3000 (3:1:1), 25 kDa PEI (6:1), or CaPO4 precipitation (4 µg pDNA/well). The supernatant was harvested, filtered (0.45 µm), and titered using 293T/17 cells. Lentivirus transductions were performed in the presence of 8 µg/ml TransduceIT™ and GFP expression was measured 72 hours post-transduction using guava easyCyte™ 5HT Flow Cytometer. Error bars represent triplicate transfection complexes titered individually. Functional titers were calculated using virus dilutions with less than 20% GFP positive cells.
 
High Transduction Efficiency with Unconcentrated Lentivirus Using TransIT®-Lenti. (A) Lentivirus was produced with the TransIT®-Lenti Transfection Reagent (3:1, vol:wt) or Lipofectamine® 2000 using pLKO.1-puro-CMV-TurboGFP™ transfer vector and the Lentivirus Packaging Mix Powered by MISSION® Genomics). The supernatant was harvested, filtered (0.45 µm), and frozen. Lentivirus transductions were performed 5 days post-plating with iCell® Motor Neurons (Cellular Dynamics International). For bothTransIT-Lenti and Lipofectamine® 2000, one microliter of unconcentrated supernatant was added per well of a 96-well plate. GFP efficiency was measured 72 hours post-transduction using guava easyCyte™ 5HT Flow Cytometer. Error bars represent the SEM of duplicate wells. (B) iCell® Motor Neurons were plated in Ibidy 35mm dishes and transduced with lentivirus produced using the TransIT®-Lenti Transfection Reagent and MISSION® vectors. Images were captured at 72 hours post-transduction with a Zeiss Axiovert S100 inverted fluorescence microscope using a 63X objective under oil.
 
 
Comparison of CaPO4, Lipofectamine® 2000 or TransIT®-Lenti Generated Lentivirus. HIV CMVeGFP Virus was produced in HEK 293FT cells using either CaPO4, Lipofectamine® 2000 or TransIT®-Lenti Transfection Reagent per the manufacturer’s protocol. Lentivirus was collected 48 hours post-transfection and concentrated by prolonged centrifugation at 9,000 x g. HT1080cells were infected with a 1:100 or 1:1000 dilution of each concentrated lentivirus. Images (above) were captured 48 hours post-transduction.

Data courtesy of Jeremy Coffin, University of Iowa Viral Vector Core

High Efficiency Transfection with TransIT®-Lenti Transfection Reagent. Adherent 293T/17 cells were transfected in a 6-well plate format using the pLKO.1-puro-CMV-TurboGFP™ transfer vector and the Lentivirus Packaging Mix Powered by MISSION® Genomics using the TransIT®-Lenti Transfection Reagent (3:1, vol:wt). GFP efficiency was measured at 48 hours post-transfection using guava easyCyte™ 5HT Flow Cytometer.  Error bars represent five transfection complexes. Images were captured at 48 hours post-transfection (10X objective) using a Zeiss Axiovert S100 inverted fluorescence microscope. The observed cell rounding and cell-cell fusion is due to high expression of the vesicular stomatitis virus G protein (VSV-G) for pseudotyping the recombinant lentivirus.

Lentivirus Production is Scalable. Adherent 293T/17 cells were transfected in a 12-well, 6-well or 100 mm plate format using the pLKO.1-puro-CMV-TurboGFP™ transfer vector and the Lentivirus Packaging Mix Powered by MISSION® Genomics at a 1:1 ratio, and the TransIT®-Lenti Transfection Reagent (3:1, vol:wt). The supernatant was harvested, filtered (0.45 µm), and titered using 293T/17 cells. Lentivirus transductions were performed in the presence of 8 µg/ml TransduceIT™ and GFP expression was measured 72 hours post-transduction using guava easyCyte™ 5HT Flow Cytometer. Error bars represent triplicate transfection complexes titered individually. Functional titers were calculated using virus dilutions with less than 20% GFP positive cells.

Resources

Specifications

Storage Conditions
TransIT®-Lenti Transfection Reagent: Store at -20°C
Lentivirus Packaging Mix Powered by MISSION® Genomics: Multiple storage conditions – see individual bottles for specific recommendations
TransIT® Lentivirus System: Store at -20°C
TransduceIT™ Transduction Reagent: Store at -20°C

Product Guarantee
TransIT®-Lenti Transfection Reagent: 1 year
Lentivirus Packaging Mix Powered by MISSION® Genomics: 1 year
TransIT® Lentivirus System:
TransduceIT™ Transduction Reagent: 6 months

Usage Statement
All Configurations: For Research Use Only.

Animal Origin Statement
All Configurations: This product is animal origin free.

 

Technical Product Literature

Full Protocols
TransIT® Lentivirus System Full Protocol (PDF)
TransIT®-Lenti Full Transfection Protocol (PDF)

Quick Reference Protocols
TransIT® Lentivirus System Quick Ref Protocol (PDF)
TransIT®-Lenti Quick Ref Protocol (PDF)

Product Data Sheets
Lentivirus Packaging Mix Product Data Sheet (PDF)
TransduceIT™ Reagent Product Data Sheet (PDF)

SDS
Lentivirus Packaging Mix SDS (PDF)
TransduceIT™ Reagent SDS (PDF)
TransIT® Lentivirus System SDS (PDF)
TransIT®-Lenti SDS (PDF)

FAQs

See the TransIT-Lenti FAQs

Using transfection reagents and enhancers from Mirus has given our platform a competitive advantage. Increasing efficiency and lowering costs for all of our programs.

Sally Mader, PhD
ZYZ Theraputics

Packaging Update Alert

We are currently transitioning to a new packaging design to ensure consistency across our product portfolio, including tube cap color. During this transition, we will continue to use existing stocks of packaging for each product line before switching to the new design. As a result, you may receive shipments containing products in either packaging configuration. We do not anticipate any impact to the quality of these products. If you have any questions or concerns, please don’t hesitate to contact our Technical Support team at mirusbio_techsupport@milliporesigma.com